Profile data is unavailable for this security.
About the company
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102’s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.
- Revenue in CAD (TTM)0.00
- Net income in CAD-6.82m
- Incorporated2018
- Employees--
- LocationThiogenesis Therapeutics Corp4 King Street West, Suite 401Toronto M5H 1B6CanadaCAN
- Phone+1 (647) 846-7766
- Websitehttps://www.thiogenesis.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurothera Labs Inc | 0.00 | -209.09k | 15.73m | -- | -- | 3.76 | -- | -- | -0.0116 | -0.0116 | 0.00 | 0.0493 | 0.00 | -- | -- | -- | -19.28 | -- | -21.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -143.95 | -- | -- | -- |
| Sirona Biochem Corp | -16.37k | -2.67m | 15.85m | -- | -- | -- | -- | -- | -0.0105 | -0.0105 | -0.00006 | -0.0134 | -0.0171 | -- | 1.61 | -- | -278.90 | -173.09 | -- | -383.49 | -- | -- | -- | -1,405.28 | -- | -5.73 | -- | -- | -94.82 | -51.37 | 28.52 | -- | -- | -- |
| Numinus Wellness Inc | 5.33m | -10.67m | 16.32m | 35.00 | -- | -- | -- | 3.06 | -0.0366 | -0.0481 | 0.0175 | -0.0049 | 0.5827 | -- | 3.41 | -- | -116.67 | -77.90 | -231.32 | -88.05 | 44.96 | 31.24 | -200.23 | -325.94 | -- | -- | 3.02 | -- | -82.02 | -- | 51.75 | -- | -- | -- |
| Hemostemix Inc | 0.00 | -3.40m | 17.60m | -- | -- | -- | -- | -- | -0.03 | -0.03 | 0.00 | -0.0188 | 0.00 | -- | -- | -- | -453.77 | -579.31 | -- | -- | -- | -- | -- | -- | -- | -6.01 | -- | -- | -- | -- | -4.57 | -- | -- | -- |
| Avicanna Inc | 25.50m | -1.88m | 21.99m | 38.00 | -- | 6.63 | -- | 0.8627 | -0.0165 | -0.0165 | 0.2262 | 0.0264 | 1.22 | 2.89 | 10.84 | -- | -9.02 | -61.54 | -51.98 | -226.72 | 51.95 | 49.33 | -7.37 | -150.05 | 0.3804 | -- | 0.00 | -- | 51.62 | 172.88 | 58.62 | -- | -44.27 | -- |
| Thiogenesis Therapeutics Corp | 0.00 | -6.82m | 28.51m | -- | -- | 13.24 | -- | -- | -0.1439 | -0.1439 | 0.00 | 0.0415 | 0.00 | -- | -- | -- | -173.15 | -- | -216.52 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.87 | -- | -- | -- |
| Principal Technologies Inc | 262.84k | -4.32m | 29.19m | -- | -- | -- | -- | 111.07 | -0.1043 | -0.1072 | 0.0063 | -0.0126 | 0.2272 | -- | 1.68 | -- | -372.16 | -- | -2,615.25 | -- | -- | -- | -1,637.81 | -- | -- | -223.78 | -- | -- | -44.22 | -- | -162.24 | -- | -- | -- |
| Resverlogix Corp | 0.00 | -9.63m | 31.65m | 18.00 | -- | -- | -- | -- | -0.0339 | -0.0339 | 0.00 | -0.4205 | 0.00 | -- | -- | 0.00 | -91.25 | -- | -- | -- | -- | -- | -- | -- | 0.0248 | -1.30 | -- | -- | -- | -- | 54.39 | -- | -- | -- |
| Microbix Biosystems Inc | 18.59m | -2.25m | 31.87m | 69.00 | -- | 1.15 | -- | 1.71 | -0.0161 | -0.0161 | 0.1344 | 0.1992 | 0.4923 | 1.12 | 6.44 | -- | -5.95 | 3.86 | -6.48 | 4.37 | 53.02 | 55.92 | -12.08 | 6.37 | 5.17 | -2.23 | 0.196 | -- | -26.81 | 12.04 | -163.80 | -- | -0.4115 | -- |
| MustGrow Biologics Corp | 7.54m | -6.37m | 39.67m | 0.00 | -- | 12.75 | -- | 5.26 | -0.1206 | -0.1206 | 0.1435 | 0.0494 | 1.45 | 5.49 | 45.16 | -- | -122.84 | -54.87 | -193.93 | -66.95 | 14.51 | -- | -84.52 | -341.26 | 1.25 | -103.31 | 0.1671 | -- | -91.55 | -- | -622.18 | -- | -- | -- |
| Briacell Therapeutics Corp | 0.00 | -38.97m | 41.26m | 22.00 | -- | 0.7915 | -- | -- | -72.33 | -72.33 | 0.00 | 7.19 | 0.00 | -- | -- | 0.00 | -246.96 | -63.88 | -359.42 | -70.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -449.14 | -- | -- | -- |
